Related Experiment Video
Updated: Jun 27, 2026

06:21
Adaptable Angled Stereotactic Approach for Versatile Neuroscience Techniques
Published on: May 7, 2020
Stereotactic surgery of nucleus tegmenti pedunculopontine [corrected]
P Mazzone1, S Sposato, A Insola
1Functional and Stereotactic Neurosurgery, CTO, ASL RMC, Rome, Italy. stereomaz@libero.it
British Journal of Neurosurgery
|December 17, 2008
Summary
Deep brain stimulation (DBS) of the pedunculopontine nucleus (PPTg) offers a safe and effective treatment for Parkinson's disease (PD) patients, significantly improving gait and speech. This advanced surgical technique targets levodopa-resistant symptoms.
Area of Science:
- Neurosurgery
- Neurology
- Movement Disorders
Background:
- Parkinson's disease (PD) often presents with motor symptoms like gait disturbances and postural abnormalities that are resistant to levodopa treatment.
- The pedunculopontine nucleus (PPTg) has emerged as a potential deep brain stimulation (DBS) target for these specific PD symptoms.
Purpose of the Study:
- To detail the pre-operative planning, surgical procedures, and outcomes of DBS targeting the PPTg in human patients.
- To compare the efficacy and safety of traditional indirect DBS targeting with a newer direct targeting method for the PPTg.
Main Methods:
- A cohort of thirteen patients with Parkinson's disease underwent PPTg DBS.
- Surgical approaches included an indirect method using ventriculography (5 patients) and a direct method utilizing CT scans and 3D PPTg visualization (8 patients).
- Clinical outcomes were assessed based on improvements in gait, freezing, speech, and arising from a chair.
Main Results:
- No major complications were reported following PPTg DBS implantation.
- The direct targeting method demonstrated reduced variability compared to the traditional indirect approach.
- Significant clinical improvements were observed in gait disturbances, freezing episodes, speech, and the ability to arise from a chair.
Conclusions:
- Deep brain stimulation of the PPTg is a safe and effective therapeutic option for Parkinson's disease patients, particularly for levodopa-resistant motor symptoms.
- The direct targeting method for PPTg DBS provides superior anatomical adaptation and precision compared to indirect methods.
- PPTg DBS successfully ameliorates key non-dopaminergic symptoms in Parkinson's disease, offering a new avenue for treatment.

